Study Title
LOXO-TRK-15003: A Phase 1/2 Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors
Protocol ID
LOXO-TRK-15003
Condition/s
Solid Tumors Harboring NTRK Fusion
Diagnosis Stage
New diagnosis
Relapse/ refractory
Relapse/ refractory
Location
NSW, VIC, WA
Sponsor
Bayer
Links
Trial Status
Closed to Recruitment
Sites
Sydney Children's Hospital
Women and Children's Hospital
Royal Children's Hospital
Women and Children's Hospital
Royal Children's Hospital
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
up to 21 years
International registry ID's
NCT02637687
| Study Title | LOXO-TRK-15003: A Phase 1/2 Study of the Oral TRK Inhibitor LOXO-101 in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors |
|---|---|
| Protocol ID | LOXO-TRK-15003 |
| Disease (Sub Disease) | Solid Tumors Harboring NTRK Fusion |
| Diagnosis Stage | New diagnosis Relapse/ refractory |
| Location | NSW / VIC / WA |
| Sponsor | Bayer |
| Links | https://clinicaltrials.gov/ct2/show/NCT02637687 |
| Trial Status | Closed to Recruitment |
| Trial Open Date | 11/09/2017 |
| Sites | Sydney Children's Hospital / Women and Children's Hospital/ Royal Children's Hospital |
| Study Type | Treatment |
| Phase | Phase 1/2 |
| Age Eligibility | up to 21 years |
| International registry ID's | NCT02637687 |